<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89132">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02026752</url>
  </required_header>
  <id_info>
    <org_study_id>HIVQPS-US12-001</org_study_id>
    <secondary_id>HIVQPS-US12-002</secondary_id>
    <nct_id>NCT02026752</nct_id>
  </id_info>
  <brief_title>Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay</brief_title>
  <official_title>Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gen-Probe, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gen-Probe, Incorporated</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to obtain plasma samples from Human Immunodeficiency Virus Type 1 (HIV-1)
      infected individuals that have viral loads across the dynamic range of the Aptima HIV-1
      assay. The plasma samples will be tested in a method comparison study to support the
      approval of the Aptima HIV-1 assay on Gen-Probe's Panther testing system. The objective of
      the method comparison study is to evaluate the clinical utility of the Aptima HIV-1 assay by
      comparing the results to the FDA-licensed COBAS assay (Roche Molecular Systems, Inc.,
      Branchburg, New Jersey) in plasma samples that have viral loads across the dynamic range of
      the Aptima HIV-1 assay.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Quantitative detection of HIV-1 RNA</measure>
    <time_frame>single baseline visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Regression parameters (intercept and slope) will be estimated from method comparison analysis.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Study Population</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected male and female subjects â‰¥15 years of age who are attending participating US
        medical facilities will be eligible to enroll. Participating sites may include academic
        institutions with clinical divisions, infectious disease clinics, and other medical
        facilities such as sexually transmitted infection, HIV, and public health facilities
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  The subject has documented HIV infection

          -  The subject is at least 15 years of age at the time of enrollment

          -  For ART subjects, subject has documented HIV-1 RNA levels above the lower limit of
             quantitation of an FDA-approved assay in a sample collected in the past 90 days.

          -  The subject (and/or legally authorized representative, if allowed) is willing and
             able to provide written informed consent before providing a specimen (a minor will
             need the documented consent of his/her parent or legal guardian, unless the site has
             an institutional review board  [IRB]-approved waiver for parental consent for
             minors).

        Exclusion Criteria

          -  A potential subject will be ineligible for the study if the subject, clinician, or
             medical record reports any of the following:

          -  Subject's HIV disease stage and/or current ART status is unknown.

          -  It is unknown if current or previous ART was changed or stopped due to therapy
             failure.

          -  For non-ART subjects, subject was previously on ART in the past 30 days

          -  Subject already participated in this study and subject's previous sample(s) was
             provided and not withdrawn (ie, subject has an evaluable sample in the study)

          -  Subject has a history of illness that the principal investigator (PI) or designee
             considers could interfere with or affect the conduct, results, and/or completion of
             the study

          -  Subject has a history of illness that the PI or designee considers could create an
             unacceptable risk to the subject if enrolled in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer L Reid, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hologic Gen-Probe</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD - AnitViral Research Center (AVRC)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Mehta, MD</last_name>
      <phone>858-822-4092</phone>
      <email>srmehta@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Sanjay Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kozal, MD</last_name>
      <phone>203-737-4040</phone>
      <email>michael.kozal@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Kozal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami - AIDS Clinical Research Unit</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Fischl, MD</last_name>
      <phone>305-243-8125</phone>
      <email>m.fischl@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Margaret Fischl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wishard Health Services</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Davis, MD</last_name>
      <phone>317-274-3391</phone>
      <email>ThDavis@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Taylor, MD</last_name>
      <phone>504-568-4132</phone>
      <email>staylo2@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Stephanie Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timothy Amukele, MD</last_name>
      <phone>410-502-5296</phone>
      <email>tamukele@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Amukele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Leider, MD</last_name>
      <phone>718-918-3669</phone>
      <email>Jason.Leider@NBHN.net</email>
    </contact>
    <investigator>
      <last_name>Jason Leider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 27, 2014</lastchanged_date>
  <firstreceived_date>December 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
